Now ‘quality’ competition rather than weight lossFood intake is maintained, but weight loss is lost by increasing energy consumption
With the <a href="https://healthylife7.com/illegal-imports-of-obesity-drugs-surge-3-5-fold-in-korea/” title=”Illegal imports of obesity drugs surge 3.5-fold in Korea”>obesity treatment craze sweeping the world, the pharmaceutical bio industry has already begun the next generation of drug competition. Unlike the GLP-1 family, which suppresses appetite, “obesity treatment 2.0” aims to lose weight by increasing energy consumption while maintaining the amount of meals. Attention is focusing on whether it will be an alternative to those who suffer side effects such as Hugo Bee and Mountaineer
The core of obesity treatment 2.0 is a ‘healthy diet’. Since the amount of meals is maintained, there are no side effects of the gastrointestinal tract such as nausea, and muscle mass does not decrease. Instead, it burns more unnecessary fat to use more energy. It is a new diet strategy that can only select and lose fat in our body
According to a recent UC Berkeley study, the low-molecular compound “TOFA” has been shown to reduce weight by increasing energy consumption in the body. As a result of administering TOFA to obese mice for four weeks, the researchers lost about 18% of their average weight
It should be noted that there was no significant change in the amount of intake even after administration of TOFA, and the weight lost was mainly body fat. It is differentiated from the loss of muscles by reducing the amount of obesity treatments currently used, such as Hugo Bee and Mountaineer. According to a meta-analysis of GLP-1 drugs conducted last year, about 25% of the weight lost from drug treatment was due to muscle loss
Mice administered TOFA had an approximately 18% increase in energy consumption than usual in a temperature-23-degree environment. The amount of activity remained the same, but even if I stayed still, I burned more fat to create energy. This means that the metabolism of the cell itself has increased. It is a way to eat food as usual, keep your muscles, and lose only unnecessary fat
Even if you stop administering it Phenomena’ was much less than conventional obesity treatments. Since there was no change in food intake, there was no weight rebound even if treatment was stopped. The researchers explained, “Suspending GLP-1 drugs increases weight immediately and steeply, but TOFA drugs did not rebound significantly.”
Since Hugo Bee and Mountaineero hit the pharmaceutical bio industry around the world, research on second-generation obesity treatments has been actively conducted in academia since last year. Academia has already found a number of candidate substances, and some are even conducting clinical trials with pharmaceutical companies
Eolo Pharma, a Uruguay-based pharmaceutical company, developed a candidate substance for an obesity treatment called “SANA” last year with local university researchers. Last year, the Nature Sisters published the results of phase 1 clinical trials in humans, and it was found that they lost about 3% of their weight within 15 days of administration. It has proven both safety and drug effectiveness
SANA’s principle is to burn more fat while maintaining food intake. SANA causes mitochondria in adipocytes to consume more energy. If TOFA is the way to make less fat and burn more fat, SANA focuses all its power on fat burning
These ‘energy-consumption’ obesity treatments are already entering the clinical development stage of the pharmaceutical bio industry. In the same way, HU6, an oral candidate being developed by Rivers Pharmaceuticals, an American biotechnology company, encourages more energy consumption. The goal is to minimize muscle loss by using fat as a major energy patients with obesity and metabolic diseases
The competition standard for next-generation obesity treatments is shifting from the amount of weight loss to the quality. It’s not just about how many kilograms you lost, it’s about how much fat you lose and how much you preserve your muscles. Experts are also looking at ways to combine the “less eating” method and the “burning more fat” method in the future
Researchers at UC Berkeley, who studied TOFA, said, “When combined with existing obesity treatments, it can induce greater weight loss,” adding, “It is a strategy to maintain food intake control and metabolic health recovery.” SANA researchers also said, “The GLP-1 family has made important progress in treating obesity, but it still needs to be supplemented. Measures to minimize muscle loss and weight rebound should be added.”
